Structural basis for the highly selective inhibition of MMP-13.

[1]  Seth M. Cohen,et al.  New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. , 2004, Journal of the American Chemical Society.

[2]  I. Bertini,et al.  Crystal structure of the catalytic domain of human matrix metalloproteinase 10. , 2004, Journal of molecular biology.

[3]  J. Foidart,et al.  Crystal structure of the catalytic domain of MMP-16/MT3-MMP: characterization of MT-MMP specific features. , 2004, Journal of molecular biology.

[4]  J. Skotnicki,et al.  Design strategies for the identification of MMP-13 and Tace inhibitors. , 2003, Current opinion in drug discovery & development.

[5]  H. Matter,et al.  Tetrahydroisoquinoline-3-carboxylate based matrix-metalloproteinase inhibitors: design, synthesis and structure-activity relationship. , 2002, Bioorganic & medicinal chemistry.

[6]  C. Janson,et al.  Structure of the C-terminally truncated human ProMMP9, a gelatin-binding matrix metalloproteinase. , 2002, Acta crystallographica. Section D, Biological crystallography.

[7]  A. Henney,et al.  Crystal structure of human MMP9 in complex with a reverse hydroxamate inhibitor. , 2002, Journal of molecular biology.

[8]  Ekaterina Morgunova,et al.  Structural insight into the complex formation of latent matrix metalloproteinase 2 with tissue inhibitor of metalloproteinase 2 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[9]  A Zien,et al.  Anabolic and catabolic gene expression pattern analysis in normal versus osteoarthritic cartilage using complementary DNA-array technology. , 2001, Arthritis and rheumatism.

[10]  H. Nar,et al.  Crystal structure of human macrophage elastase (MMP-12) in complex with a hydroxamic acid inhibitor. , 2001, Journal of molecular biology.

[11]  R. Huber,et al.  Substrate specificity determinants of human macrophage elastase (MMP-12) based on the 1.1 A crystal structure. , 2001, Journal of molecular biology.

[12]  H. Brandstetter,et al.  Structure-based design and synthesis of potent matrix metalloproteinase inhibitors derived from a 6H-1,3,4-thiadiazine scaffold. , 2001, Journal of medicinal chemistry.

[13]  R. Palermo,et al.  Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[14]  D. Moras,et al.  Crystal structure of the stromelysin-3 (MMP-11) catalytic domain complexed with a phosphinic inhibitor mimicking the transition-state. , 2001, Journal of molecular biology.

[15]  A. Jeng,et al.  The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. , 2001, Current medicinal chemistry.

[16]  T. Baker,et al.  Development of new carboxylic acid-based MMP inhibitors derived from functionalized propargylglycines. , 2001, Journal of medicinal chemistry.

[17]  Robert Powers,et al.  Structure-based design of a novel, potent, and selective inhibitor for MMP-13 utilizing NMR spectroscopy and computer-aided molecular design , 2000 .

[18]  P. Tucker,et al.  Two crystal structures of human neutrophil collagenase, one complexed with a primed- and the other with an unprimed-side inhibitor: implications for drug design. , 2000, Journal of medicinal chemistry.

[19]  X. Zhang,et al.  Solution structure of the catalytic domain of human collagenase-3 (MMP-13) complexed to a potent non-peptidic sulfonamide inhibitor: binding comparison with stromelysin-1 and collagenase-1. , 2000, Journal of molecular biology.

[20]  M. Michaelides,et al.  Recent advances in matrix metalloproteinase inhibitors research. , 1999, Current pharmaceutical design.

[21]  A. Gearing,et al.  Design and therapeutic application of matrix metalloproteinase inhibitors. , 1999, Chemical reviews.

[22]  Tom L. Blundell,et al.  X-RAY STRUCTURE OF GELATINASE A CATALYTIC DOMAIN COMPLEXED WITH A HYDROXAMATE INHIBITOR , 1999 .

[23]  H Matter,et al.  Quantitative structure-activity relationship of human neutrophil collagenase (MMP-8) inhibitors using comparative molecular field analysis and X-ray structure analysis. , 1999, Journal of medicinal chemistry.

[24]  R. Poorman,et al.  Synthesis of a series of stromelysin-selective thiadiazole urea matrix metalloproteinase inhibitors. , 1999, Journal of medicinal chemistry.

[25]  H. V. Van Wart,et al.  Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors , 1999, Nature Structural Biology.

[26]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[27]  J. Calvete,et al.  Crystal structure of the complex formed by the membrane type 1‐matrix metalloproteinase with the tissue inhibitor of metalloproteinases‐2, the soluble progelatinase A receptor , 1998, The EMBO journal.

[28]  J. Marshall,et al.  Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Babine,et al.  MOLECULAR RECOGNITION OF PROTEIN-LIGAND COMPLEXES : APPLICATIONS TO DRUG DESIGN , 1997 .

[30]  H. V. Van Wart,et al.  Understanding the P1' specificity of the matrix metalloproteinases: effect of S1' pocket mutations in matrilysin and stromelysin-1. , 1996, Biochemistry.

[31]  M. Browner,et al.  Matrilysin-inhibitor complexes: common themes among metalloproteases. , 1996, Biochemistry.

[32]  D. Wernicke,et al.  Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. , 1996, The Journal of rheumatology.

[33]  J. Springer,et al.  Stromelysin‐1: Three‐dimensional structure of the inhibited catalytic domain and of the C‐truncated proenzyme , 1995, Protein science : a publication of the Protein Society.

[34]  W. Bode,et al.  Structural features of a superfamily of zinc-endopeptidases: the metzincins. , 1995, Current opinion in structural biology.

[35]  M. Browner,et al.  Crystal structures of matrilysin-inhibitor complexes , 1995 .

[36]  P. Reinemer,et al.  The metzincins — Topological and sequential relations between the astacins, adamalysins, serralysins, and matrixins (collagenases) define a super family of zinc‐peptidases , 1995, Protein science : a publication of the Protein Society.

[37]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[38]  C. López-Otín,et al.  Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. , 1994, The Journal of biological chemistry.

[39]  M. Walid Qoronfleh,et al.  Structure of human neutrophil collagenase reveals large S1′ specificity pocket , 1994, Nature Structural Biology.

[40]  A M Hassell,et al.  Structure of the catalytic domain of fibroblast collagenase complexed with an inhibitor. , 1994, Science.

[41]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[42]  G Murphy,et al.  A novel coumarin‐labelled peptide for sensitive continuous assays of the matrix metalloproteinases , 1992, FEBS letters.

[43]  A Yasui,et al.  Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. , 1990, European journal of biochemistry.

[44]  Wolfgang Kabsch,et al.  Automatic indexing of rotation diffraction patterns , 1988 .

[45]  Petr Kuzmic,et al.  Practical Robust Fit of Enzyme Inhibition Data , 2004, Numerical Computer Methods, Part D.

[46]  A. Parker,et al.  Expression profiling of metalloproteinases and their inhibitors in cartilage. , 2004, Arthritis and rheumatism.

[47]  K. Hasty,et al.  Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. , 2000, Arthritis and rheumatism.

[48]  S. Zucker,et al.  Inhibition of matrix metalloproteinases : therapeutic applications , 1999 .

[49]  Planar Phospholipid,et al.  RECENT ADVANCES IN , 1986 .